Focus: Xeltis is a tissue engineering-focused biotech company headquartered in Eindhoven, Netherlands, specializing in regenerative solutions for cardiovascular, nephrology, and women's health applications. The company operates as a public entity with a heavily concentrated revenue model centered on contraceptive products.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Strong science and IP moat in regenerative medicine, but severe revenue concentration and thin hiring pipeline create execution risk—best suited for early-career scientists willing to build something from the ground up rather than those seeking rapid internal mobility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Only branded NDA product and revenue pillar; progestin-only formulation provides 7+ years of exclusivity runway.
Help build intelligence for Xeltis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Xeltis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NDA with patent cliff in 2027 represents minimal revenue contribution and near-term generic erosion risk.
ANDA already post-LOE with limited differentiation; generic competition eroding market share.
Post-LOE ANDA with minimal Part D penetration indicating weak commercial positioning.
3 discontinued, 20 duplicate formulations not shown
Xeltis gains EU CE mark on positive trial data for vascular access graft - Clinical Trials Arena
Xeltis gains EU CE mark on positive trial data for vascular access graft Clinical Trials Arena
Xeltis gains EU CE mark on positive trial data for vascular access graft - Clinical Trials Arena
Xeltis gains EU CE mark on positive trial data for vascular access graft Clinical Trials Arena
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Four-Year Outcomes of aXess Arteriovenous Conduit in Hemodialysis Patients: Insights from Two Case Reports of the aXess FIH Study.
Computational modeling of endogenous tissue restoration in biodegradable implants: Bridging scaffold degradation and neo-tissue adaptation.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo